Research and Recommendations on the Contribution of the Pharmaceutical Industry to Extending Healthy Life Expectancy and Driving Economic Growth - Toward the Future of the Pharmaceutical Industry
April 20, 2023
Japan Pharmaceutical Manufacturers Association
The Japan Pharmaceutical Manufacturers Association (JPMA) is pleased to announce that the report "Study and Proposal on the Contribution of the Pharmaceutical Industry to Extending Healthy Life Span and Driving Economic Growth: Toward the Future of the Pharmaceutical Industry" developed by the Study Group on Extending Healthy Life Span and Driving Economic Growth (hereinafter referred to as the Study Group) is now available on the JPMA website. The report, "Research and Recommendations on the Contribution of the Pharmaceutical Industry to Extending Healthy Life Expectancy and Driving Economic Growth: Toward the Future of the Pharmaceutical Industry," is available on the website of the Pharmaceutical Manufacturers Association of Japan.
The study group was established in December 2021, with the participation of experts who are leading academic research on the state of healthcare as a whole, to discuss the contribution of the pharmaceutical industry from an objective and neutral standpoint, and to present a vision of what the pharmaceutical industry should aim for based on the evidence obtained from the evaluation and analysis. The Pharmaceutical Manufacturers Association of Japan (PMAJ) has supported this study group to the best of its ability since its establishment in December 2021.
Through this report, we have received suggestions on the importance of building evidence to show how the pharmaceutical industry contributes to the extension of healthy life expectancy and economic growth, as well as to promote the sharing of issues and problems related to the pharmaceutical industry among the public. The Pharmaceutical Manufacturers Association of Japan (PMAJ) will actively pursue ongoing efforts to promote further research.
This report was presented by the chairperson, Dr. Manami Hori, to Mr. Koichi Ando, Director, Pharmaceutical Industry Promotion and Medical Information Planning Division, Medical Policy Bureau, Ministry of Health, Labour and Welfare.
Reference
Study Group on Extending Healthy Life Expectancy and Driving Economic Growth
Discussion will be held from an objective and neutral standpoint on the promotion of research to build evidence to show how the pharmaceutical industry contributes to healthy life expectancy extension and economic growth, and on the progress in sharing issues related to the pharmaceutical industry with the public.
Background and Issues Concerning the Establishment of the Study Group
- Many people wish to live long and healthy lives. People also hope that the economy of the country as a whole will grow stably, that a sustainable social security system will be ensured, and that concerns about illness and old age will be eliminated.
- Health, medical care, and long-term care are the fundamental systems that support people's health, longevity, and security of life. Many entities, both public and private, are involved in the operation of healthcare, medical care, and long-term care and in the provision of services. Among them, the pharmaceutical industry is a key industry that plays a major role in protecting people's health, mainly through the development of new drugs.
- However, it is not clear to what extent people's trust in and expectations of the pharmaceutical industry are high. It is also difficult to say that people have a sufficient understanding of the contribution that pharmaceuticals make to extending healthy life expectancy based on solid evidence. Furthermore, there is little evidence to date on the extent to which extending people's healthy life expectancy leads to economic growth for the country as a whole.
- In order for the pharmaceutical industry to further gain people's trust and gain their understanding of the potential of pharmaceuticals to extend healthy life expectancy and to contribute to economic growth, it is necessary to (i) analyze and understand the current level ofpeople'sawareness and trust of pharmaceuticals and the pharmaceutical industry, and (ii) summarize and present evidence on the extension of healthy life expectancy through the use of pharmaceuticals. (i) to analyze and understand the current status of people's awareness and trust in pharmaceuticals and the pharmaceutical industry, (ii) to summarize and present evidence on the extension of healthy life expectancy through pharmaceuticals, and (iii) to present evidence on the economic growth driver through the extension of healthy life expectancy.
Six "Study Group Members" from front left
Dr. Reine Takaku, Dr. Hideo Yasunaga, Dr. Kazuji Inami, Dr. Manami Hori (Chair), Dr. Toshiki Mano, Dr. Koichi Masuyama
Parties involved from back left
Pharmaceutical Manufacturers Association of Japan: Masaomi Akana, Chair, Industrial Policy Committee; Hiroaki Ueno, Vice Chair; Yasushi Okada, Chair; Junichi Shiraishi, President
For inquiries, please contact
Public Relations Department, Japan Pharmaceutical Manufacturers Association (JPMA)
- Phone
- 03-3241-0374
- Inquiry form
- www.jpma.or.jp/inquiry/